Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Background The large number of patients worldwide infected with the SARS-CoV-2 virus
has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) …

Background COVID-19 progression is associated with an increased risk of arterial and
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …

In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a
thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly …

Introduction The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients
remain unclear. We present the 90-day results from the randomised, open-label, parallel …

Background Many COVID-19 patients develop a hyperinflammatory response which
activates blood coagulation and may contribute to the occurrence of thromboembolic …

Abstract Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …

COVID-19 is associated with a high incidence of thrombotic complications, which can be
explained by the complex and unique interplay between coronaviruses and endothelial …

Coagulation dysfunction and thrombosis are major complications in patients with
coronavirus disease 2019 (COVID‐19). Patients on oral anticoagulants (OAC) prior to …

Background Observational studies have suggested a higher risk of thrombotic events in
patients with coronavirus disease 2019 (COVID-19). Moreover, elevated D-dimer levels …